Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 734-741

  Jekle, Andreas ^a   Chhabra, Milloni ^a   Lochner, Adriane ^a,c   Meier, Sonja ^a   Chow, Eugene ^a,d   Brandt, Michael ^b   Sankuratri, Surya ^a   Cammack, Nick ^a   Heilek, Gabrielle ^a  

^a ROCHE BIOSCIENCE   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

^d Roche Diagnostics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13; MONOCLONAL ANTIBODY 3952; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CROSS RESISTANCE; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; BINDING SITES; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; EPITOPES; HIV; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5;

EID: 75749132771     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00841-09     Document Type: Article

References (29)

1. Aarons, E. J., S. Beddows, T. Willingham, L. Wu, and R. A. Koup. 2001. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 287:382-390.
2. Agrawal, L., Z. VanHorn-Ali, E. A. Berger, and G. Alkhatib. 2004. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 103:1211-1217.
3. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
4. Carter, P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1:118-129.
5. Cormier, E. G., D. N. Tran, L. Yukhayeva, W. C. Olson, and T. Dragic. 2001. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75:5541-5549.
6. De Clercq, E., N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, K. De Vreese, Z. Debyser, B. Rosenwirth, P. Peichl, R. Datema, et al. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38:668-674.
7. de Roda Husman, A. M., and H. Schuitemaker. 1998. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol. 6:244-249.
8. Doranz, B. J., Z. H. Lu, J. Rucker, T. Y. Zhang, M. Sharron, Y. H. Cen, Z. X. Wang, H. H. Guo, J. G. Du, M. A. Accavitti, R. W. Doms, and S. C. Peiper. 1997. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71:6305-6314.
9. Dragic, T., A. Trkola, S. W. Lin, K. A. Nagashima, F. Kajumo, L. Zhao, W. C. Olson, L. Wu, C. R. Mackay, G. P. Allaway, T. P. Sakmar, J. P. Moore, and P. J. Maddon. 1998. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72:279-285.
10. Huang, C. C., S. N. Lam, P. Acharya, M. Tang, S. H. Xiang, S. S. Hussan, R. L. Stanfield, J. Robinson, J. Sodroski, I. A. Wilson, R. Wyatt, C. A. Bewley, and P. D. Kwong. 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934.
11. Jacobson, J. M., M. S. Saag, M. A. Thompson, M. A. Fischl, R. Liporace, R. C. Reichman, R. R. Redfield, C. J. Fichtenbaum, B. S. Zingman, M. C. Patel, J. D. Murga, S. M. Pemrick, P. D'Ambrosio, M. Michael, H. Kroger, H. Ly, Y. Rotshteyn, R. Buice, S. A. Morris, J. J. Stavola, P. J. Maddon, A. B. Kremer, and W. C. Olson. 2008. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 198:1345-1352.
12. Jekle, A., E. Chow, E. Kopetzki, C. Ji, M. J. Yan, R. Nguyen, S. Sankuratri, N. Cammack, and G. Heilek. 2009. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Res. 83:257-266.
13. Ji, C., M. Brandt, M. Dioszegi, A. Jekle, S. Schwoerer, S. Challand, J. Zhang, Y. Chen, L. Zautke, G. Achhammer, M. Baehner, S. Kroetz, G. Heilek-Snyder, R. Schumacher, N. Cammack, and S. Sankuratri. 2007. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res. 74:125-137.
14. Ji, C., E. Kopetzki, A. Jekle, K. G. Stubenrauch, X. Liu, J. Zhang, E. Rao, T. Schlothauer, S. Fischer, N. Cammack, G. Heilek, S. Ries, and S. Sankuratri. 2009. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J. Biol. Chem. 284:5175-5185.
15. Kopetzki, E., A. Jekle, C. Ji, E. Rao, J. Zhang, S. Fischer, N. Cammack, S. Sankuratri, and G. Heilek. 2008. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virol. J. 5:56.
16. Lalezari, J., G. K. Yadavalli, M. Para, G. Richmond, E. Dejesus, S. J. Brown, W. Cai, C. Chen, J. Zhong, L. A. Novello, M. M. Lederman, and G. M. Subramanian. 2008. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J. Infect. Dis. 197:721-727.
17. Landovitz, R. J., J. B. Angel, C. Hoffmann, H. Horst, M. Opravil, J. Long, W. Greaves, and G. Fatkenheuer. 2008. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113-1122.
18. Lee, B., M. Sharron, C. Blanpain, B. J. Doranz, J. Vakili, P. Setoh, E. Berg, G. Liu, H. R. Guy, S. R. Durell, M. Parmentier, C. N. Chang, K. Price, M. Tsang, and R. W. Doms. 1999. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:9617-9626.
19. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiplyexposed individuals to HIV-1 infection. Cell 86:367-377.
20. Meanwell, N. A., and J. F. Kadow. 2007. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Investig. Drugs 8:669-681.
21. Nolan, K. M., G. Q. Del Prete, A. P. Jordan, B. Haggarty, J. Romano, G. J. Leslie, and J. A. Hoxie. 2009. Characterization of a human immunodefi-ciency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J. Virol. 83:3798-3809.
22. Olson, W., T. J. Ketas, M. Franti, S. E. Kuhmann, J. P. Moore, and P. J. Maddon. 2006. The CCR5 mAB Pro 140 and small-molecule CCR5 antagonists possess complementary HIV-1 resistance profiles, poster H-241, p. 273. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
23. Olson, W. C., G. E. Rabut, K. A. Nagashima, D. N. Tran, D. J. Anselma, S. P. Monard, J. P. Segal, D. A. Thompson, F. Kajumo, Y. Guo, J. P. Moore, P. J. Maddon, and T. Dragic. 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73:4145-4155.
24. Platt, E. J., D. M. Shea, P. P. Rose, and D. Kabat. 2005. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J. Virol. 79:4357-4368.
25. Pugach, P., A. J. Marozsan, T. J. Ketas, E. L. Landes, J. P. Moore, and S. E. Kuhmann. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212-228.
26. Rucker, J., M. Samson, B. J. Doranz, F. Libert, J. F. Berson, Y. Yi, R. J. Smyth, R. G. Collman, C. C. Broder, G. Vassart, R. W. Doms, and M. Parmentier. 1996. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87:437-446.
27. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
28. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
29. Zhang, J., E. Rao, M. Dioszegi, R. Kondru, A. DeRosier, E. Chan, S. Schwoerer, N. Cammack, M. Brandt, S. Sankuratri, and C. Ji. 2007. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies. Antimicrob. Agents Chemother. 51:1386-1397.